National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia.
Department of Paediatrics, University of Otago, Christchurch, New Zealand.
JAMA. 2018 Jun 5;319(21):2190-2201. doi: 10.1001/jama.2018.5725.
There are potential benefits and harms of hyperoxemia and hypoxemia for extremely preterm infants receiving more vs less supplemental oxygen.
To compare the effects of different target ranges for oxygen saturation as measured by pulse oximetry (Spo2) on death or major morbidity.
DESIGN, SETTING, AND PARTICIPANTS: Prospectively planned meta-analysis of individual participant data from 5 randomized clinical trials (conducted from 2005-2014) enrolling infants born before 28 weeks' gestation.
Spo2 target range that was lower (85%-89%) vs higher (91%-95%).
The primary outcome was a composite of death or major disability (bilateral blindness, deafness, cerebral palsy diagnosed as ≥2 level on the Gross Motor Function Classification System, or Bayley-III cognitive or language score <85) at a corrected age of 18 to 24 months. There were 16 secondary outcomes including the components of the primary outcome and other major morbidities.
A total of 4965 infants were randomized (2480 to the lower Spo2 target range and 2485 to the higher Spo2 range) and had a median gestational age of 26 weeks (interquartile range, 25-27 weeks) and a mean birth weight of 832 g (SD, 190 g). The primary outcome occurred in 1191 of 2228 infants (53.5%) in the lower Spo2 target group and 1150 of 2229 infants (51.6%) in the higher Spo2 target group (risk difference, 1.7% [95% CI, -1.3% to 4.6%]; relative risk [RR], 1.04 [95% CI, 0.98 to 1.09], P = .21). Of the 16 secondary outcomes, 11 were null, 2 significantly favored the lower Spo2 target group, and 3 significantly favored the higher Spo2 target group. Death occurred in 484 of 2433 infants (19.9%) in the lower Spo2 target group and 418 of 2440 infants (17.1%) in the higher Spo2 target group (risk difference, 2.8% [95% CI, 0.6% to 5.0%]; RR, 1.17 [95% CI, 1.04 to 1.31], P = .01). Treatment for retinopathy of prematurity was administered to 220 of 2020 infants (10.9%) in the lower Spo2 target group and 308 of 2065 infants (14.9%) in the higher Spo2 target group (risk difference, -4.0% [95% CI, -6.1% to -2.0%]; RR, 0.74 [95% CI, 0.63 to 0.86], P < .001). Severe necrotizing enterocolitis occurred in 227 of 2464 infants (9.2%) in the lower Spo2 target group and 170 of 2465 infants (6.9%) in the higher Spo2 target group (risk difference, 2.3% [95% CI, 0.8% to 3.8%]; RR, 1.33 [95% CI, 1.10 to 1.61], P = .003).
In this prospectively planned meta-analysis of individual participant data from extremely preterm infants, there was no significant difference between a lower Spo2 target range compared with a higher Spo2 target range on the primary composite outcome of death or major disability at a corrected age of 18 to 24 months. The lower Spo2 target range was associated with a higher risk of death and necrotizing enterocolitis, but a lower risk of retinopathy of prematurity treatment.
对于接受更多或更少补充氧气的极早产儿,高氧血症和低氧血症可能存在潜在的益处和危害。
比较不同脉搏血氧饱和度(SpO2)目标范围对死亡或主要发病率的影响。
设计、设置和参与者:对 5 项随机临床试验(2005 年至 2014 年进行)的个体参与者数据进行前瞻性计划的荟萃分析,纳入胎龄<28 周的婴儿。
SpO2 目标范围较低(85%-89%)与较高(91%-95%)。
主要结局是校正年龄为 18 至 24 个月时死亡或主要残疾(双侧失明、耳聋、脑瘫≥2 级,或贝利-III 认知或语言评分<85)的复合结局。共有 4965 名婴儿被随机分组(2480 名婴儿进入较低 SpO2 目标范围,2485 名婴儿进入较高 SpO2 范围),中位胎龄为 26 周(四分位距,25-27 周),平均出生体重为 832g(标准差,190g)。较低 SpO2 目标组中 2228 名婴儿中有 1191 名(53.5%)和较高 SpO2 目标组中 2229 名婴儿中有 1150 名(51.6%)发生主要结局(风险差异,1.7%[95%CI,-1.3%至 4.6%];相对风险[RR],1.04[95%CI,0.98 至 1.09],P=0.21)。在 16 个次要结局中,11 个为无效结局,2 个明显有利于较低 SpO2 目标组,3 个明显有利于较高 SpO2 目标组。较低 SpO2 目标组中 2433 名婴儿中有 484 名(19.9%)和较高 SpO2 目标组中 2440 名婴儿中有 418 名(17.1%)死亡(风险差异,2.8%[95%CI,0.6%至 5.0%];RR,1.17[95%CI,1.04 至 1.31],P=0.01)。较低 SpO2 目标组中 2020 名婴儿中有 220 名(10.9%)和较高 SpO2 目标组中 2065 名婴儿中有 308 名(14.9%)接受了早产儿视网膜病变的治疗(风险差异,-4.0%[95%CI,-6.1%至-2.0%];RR,0.74[95%CI,0.63 至 0.86],P<0.001)。较低 SpO2 目标组中 2464 名婴儿中有 227 名(9.2%)和较高 SpO2 目标组中 2465 名婴儿中有 170 名(6.9%)发生严重坏死性小肠结肠炎(风险差异,2.3%[95%CI,0.8%至 3.8%];RR,1.33[95%CI,1.10 至 1.61],P=0.003)。
在这项对极早产儿个体参与者数据的前瞻性计划荟萃分析中,较低 SpO2 目标范围与较高 SpO2 目标范围相比,在校正年龄为 18 至 24 个月的死亡或主要残疾的主要复合结局上没有显著差异。较低 SpO2 目标范围与较高的死亡率和坏死性小肠结肠炎风险相关,但与早产儿视网膜病变治疗的风险较低相关。